Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Down – What’s Next?

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) shares gapped down before the market opened on Thursday . The stock had previously closed at $16.81, but opened at $16.05. Daiichi Sankyo shares last traded at $16.62, with a volume of 255,082 shares changing hands.

Wall Street Analyst Weigh In

Separately, Zacks Research upgraded shares of Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a research report on Tuesday, May 5th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy”.

Daiichi Sankyo Trading Up 0.7%

The company has a quick ratio of 1.85, a current ratio of 2.69 and a debt-to-equity ratio of 0.18. The firm has a 50 day moving average of $17.47 and a 200 day moving average of $19.64. The firm has a market cap of $32.07 billion, a PE ratio of 18.01, a P/E/G ratio of 1.21 and a beta of -0.25.

Daiichi Sankyo (OTCMKTS:DSNKY) last posted its quarterly earnings data on Monday, May 11th. The company reported $0.15 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.18). Daiichi Sankyo had a net margin of 12.32% and a return on equity of 15.74%. The firm had revenue of $3.76 billion during the quarter, compared to analysts’ expectations of $3.74 billion. Daiichi Sankyo has set its FY 2026 guidance at 0.910-0.910 EPS. Equities analysts anticipate that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.91 earnings per share for the current year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.